The Evidence for Oral Semaglutide in Type 2 Diabetes From a Managed Care Perspective

Advertisement

---

The Evidence for Oral Semaglutide in Type 2 Diabetes From a Managed Care Perspective

Michael Heile, MD, FAAFP;Patty Taddei-Allen, PharmD, MBA, BCACP, BCGP

December 15th 2020

ArticleARTICLES

---

Type 2 Diabetes in the US Managed Care Setting: The Burden of Disease and Rationale for an Oral Glucagon-like Peptide-1 Receptor Agonist

Tanya Dougherty, PharmD, BCPS;Michael Heile, MD, FAAFP

December 14th 2020

ArticleARTICLES

---

Efficacy of Oral Semaglutide: Overview of the PIONEER Clinical Trial Program and Implications for Managed Care

Helena W. Rodbard, MD, FACP, MACE;Tanya Dougherty, PharmD, BCPS;Patty Taddei-Allen, PharmD, MBA, BCACP, BCGP

December 13th 2020

ArticleARTICLES

---

Cardiovascular Outcomes, Safety, and Tolerability With Oral Semaglutide: Insights for Managed Care

Ildiko Lingvay, MD, MPH, MSCS;Patty Taddei-Allen, PharmD, MBA, BCACP, BCGP;Tanya Dougherty, PharmD, BCPS

December 12th 2020

ArticleARTICLES

---

The Importance of Patient-Reported Outcomes in Type 2 Diabetes: Insight From the PIONEER Program With Oral Semaglutide

Doron Schneider, MD;Patty Taddei-Allen, PharmD, MBA, BCACP, BCGP;Tanya Dougherty, PharmD, BCPS

December 11th 2020

ArticleARTICLES

---

Full Video Abstract: Evidence for Oral Semaglutide in Type 2 Diabetes

December 10th 2020

VideoARTICLES

---

Participating Faculty for the Evidence for Oral Semaglutide in Type 2 Diabetes From a Managed Care Perspective

December 9th 2020

Article